Campral

Basic Campral Information

• INN (International Nonproprietary Name): Acamprosate (acamprosate calcium).
• Brand Names Available In Australia: Campral.
• ATC Code: N07BB03.
• Forms & Dosages: Enteric‑coated, delayed‑release oral tablets; each tablet contains 333 mg acamprosate calcium (equivalent to 300 mg acamprosate); typical blister packaging (often 84 tablets per pack).
• Manufacturers In Australia: Not specified.
• Registration Status In Australia: Not specified.
• OTC / Rx Classification: Prescription medicine (Rx only).

Safety, Warnings And Patient Protection (Australia)

One common worry is: is Campral safe for someone who still drinks?

Campral (acamprosate calcium) is intended for people who have already stopped drinking and is used as an adjunct to counselling or psychosocial support.

Confirming current abstinence is a safety priority before prescribing or dispensing Campral.

Baseline renal function must be checked because Campral is primarily renally excreted.

Pregnancy and breastfeeding status should be clarified due to limited safety data in these groups.

Concurrent psychiatric comorbidity should be assessed because relapse and withdrawal can increase suicidal ideation.

High‑risk groups include the elderly with possible renal decline, pregnant or breastfeeding women where data are limited, and people with severe renal impairment where specialist advice is required.

• Immediate red flags to check at consultation:
  • Active drinking.
  • Suicidal ideation or recent self‑harm.
  • Recent creatinine or eGFR results.
  • Pregnancy test in women of childbearing potential.
  • Recent opioid or other sedative use.

Use a checklist to obtain informed consent and document the discussion covering likely benefits, common side effects, a monitoring plan and emergency contacts.

Advise patients to keep tablets in the original blister pack and out of reach of children.

In the pharmacy standard operating procedure (SOP) have a table that contrasts contraindications versus precautions for quick reference.

Record all counselling in the patient file and ensure clear referrals to local alcohol services, including rural outreach where available.

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Patients often ask whether age or other illnesses change how Campral is used.

Elderly patients commonly have reduced renal clearance and eGFR should be estimated before starting acamprosate.

People with chronic kidney disease need dose adjustments or should avoid Campral in severe impairment; always verify product monograph recommendations for eGFR‑based dosing.

Pregnancy and breastfeeding data are limited, so consult obstetric services and favour non‑pharmacological relapse prevention first when possible.

Psychiatric comorbidity requires a formal risk assessment for depression and suicide because withdrawal and relapse settings increase these risks.

• Baseline tests:
  • Serum creatinine/eGFR.
  • Pregnancy test if applicable.
  • Full medication reconciliation.
  • Mental‑health screen (PHQ‑9 or GAD‑7 as appropriate).

Use shared decision making to explain the modest benefit of acamprosate, the common side‑effects such as gastrointestinal upset and diarrhoea, the expected duration of therapy and the need for psychosocial support.

Refer Aboriginal and Torres Strait Islander patients to culturally appropriate services and request translation or interpreter support when needed.

Document the discussion and provide written information for the patient and carer where appropriate.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

A common question is whether Campral affects driving or safety‑sensitive work.

Campral itself is not a sedative and does not commonly impair driving when taken alone.

Residual effects from recent alcohol use or concurrent central nervous system (CNS) depressants can impair alertness.

Under Australian workplace safety law, employers and employees must manage intoxication and impairment risks in safety‑sensitive roles.

• Practical advice:
  • Avoid driving or operating heavy machinery if feeling drowsy, light‑headed or unwell.
  • Avoid alcohol while taking Campral.
  • Discuss workplace duties with the treating clinician if in a safety‑sensitive job.

When counselling, pharmacists should ask about driving, shift or night work, and duties that involve machinery or safety responsibilities.

Also review current sedative medicines and document advice given about impairment risk.

Can I Drive After Taking It In Australia?

Short answer: Campral alone does not usually cause impairment.

Do not drive if still experiencing effects from alcohol or taking other sedatives such as benzodiazepines or opioids.

Check with the prescriber or pharmacist and follow workplace safety rules if duties are safety‑sensitive.

Usage Basics

• INN (International Nonproprietary Name): Acamprosate (acamprosate calcium).
• Brand Names Available In Australia: Campral.
• ATC Code: N07BB03.
• Forms & Dosages: Enteric‑coated, delayed‑release oral tablets; 333 mg acamprosate calcium per tablet (equivalent to 300 mg acamprosate); typically supplied in blister packs often around 84 tablets per box.
• OTC / Rx Classification: Prescription medicine — patients require a prescription.

At point of care confirm brand or generic preference, tablet strength, number of tablets required and any PBS authority requirements before dispensing.

INN

The accepted nonproprietary name used internationally for this active substance.

Enteric‑Coated

A coating that protects the tablet from stomach acid and delays release until the intestine.

Delayed‑Release

Formulation designed to release the active substance later in the gut to improve tolerability.

ARTG

The Australian Register of Therapeutic Goods entry for marketed products; verify before advising on availability.

PBS

Pharmaceutical Benefits Scheme — check current listings for subsidy status and authority requirements.

Dosing Guide

Patients often ask how many tablets and when to take them.

The commonly cited adult regimen in product monographs is two 333 mg tablets three times daily for a total daily dose of 1998 mg acamprosate.

Start Campral only after the patient has stopped drinking and in conjunction with counselling or psychosocial support.

Because acamprosate is mainly renally excreted, estimate eGFR before starting and follow product‑specific dosing tables for adjustments in mild to moderate renal impairment.

Campral is generally contraindicated or not recommended in severe renal impairment; verify current Australian product information for exact eGFR cutoffs.

Hepatic impairment does not usually require dose changes because hepatic metabolism is minimal, but monitor clinically.

• Dosing actions:
  • Morning, noon and night dosing for even plasma exposure.
  • If GI upset occurs try taking doses with food or alter timing within clinician guidance.
  • Avoid abrupt discontinuation without clinician review.

What If I Miss A Dose?

Short answer: Take the missed dose as soon as you remember on the same day.

Do not double the next dose to make up for a missed one.

If it is close to the time for the next scheduled dose, skip the missed dose and continue as normal.

Interaction Chart

People ask whether Campral mixes badly with other drugs or food.

Campral is intended for patients who are already abstinent and continued alcohol use reduces its effectiveness.

As an enteric‑coated, delayed‑release tablet, there are no special food restrictions, though taking with food may help GI tolerability.

Acamprosate has low hepatic metabolism and relatively few pharmacokinetic interactions.

Be cautious with concomitant CNS depressants because of potential additive effects on alertness.

Also review nephrotoxic agents which could affect renal clearance of acamprosate.

• Immediate counselling points: avoid alcohol, report unusual drowsiness, and review all over‑the‑counter and herbal remedies.

For complex polypharmacy consider a specialist pharmacist review.

User Reports & Trends (Australian Patient Feedback Sources)

Patients commonly want to hear what others report when taking Campral in Australia.

Typical sources of consumer feedback include ProductReview, addiction support forums and clinic feedback forms.

Reported benefits most often mentioned are reduced cravings and improved ability to remain abstinent when combined with counselling.

Common adverse reports include gastrointestinal effects such as diarrhoea and cramping, plus headache and occasional sleep disturbance or anxiety.

• Typical patient concerns to address:
  • Benefit can be gradual and may take several weeks.
  • Need for concurrent psychosocial support for best outcomes.
  • Managing diarrhoea with hydration and dose timing adjustments.
  • What to do if relapse occurs — seek clinician support promptly.

When clinicians synthesise patient feedback watch for adherence barriers such as tablet burden (six tablets daily), cost and rural access issues.

Remember online reports are anecdotal; for clinical decisions rely on peer‑reviewed studies and guideline summaries.

Access & Purchase Options In Australia

Patients often ask where they can get Campral and how much it will cost.

Typical supply routes include community pharmacies (major chains and independents), hospital outpatient pharmacies and accredited online pharmacies that accept e‑prescriptions and telehealth orders.

Rural patients may experience longer delays and variable stock; plan ahead with monthly dispenses and local referrals to community alcohol services.

In our online pharmacy, campral is available without a prescription, with discreet delivery to Australia in 9‑21 days.

• Checklist for remote prescribing: confirm ARTG/PBS entitlement, ensure a clear supply plan and involve a multi‑disciplinary team for follow‑up.

For privacy and effective counselling prefer face‑to‑face or secure telehealth for the initial education session.

Mechanism & Pharmacology

Clinicians commonly want a short, accurate mechanism to explain to patients.

Acamprosate is believed to modulate neurotransmitter balance in the brain that follows alcohol cessation, helping to reduce prolonged withdrawal symptoms and craving.

The enteric‑coated, delayed‑release tablets aid gastrointestinal tolerability.

Acamprosate undergoes minimal hepatic metabolism and is primarily renally excreted, which is why renal function monitoring is important.

The ATC classification for acamprosate is N07BB03, under drugs used in alcohol dependence.

Glutamate

An excitatory neurotransmitter implicated in withdrawal hyperactivity.

GABA

An inhibitory neurotransmitter that can be downregulated with chronic alcohol use.

Enteric‑Coated

A tablet design to reduce stomach irritation and delay release.

Renal Clearance

Main elimination route for acamprosate requiring eGFR‑based consideration.

Because renal excretion predominates, dosing must consider eGFR, and because hepatic metabolism is minimal, acamprosate can be suitable when hepatic impairment limits other agents.

Indications & Off‑Label Uses

Patients often ask what Campral is approved to treat and whether it can be used for other problems.

The approved indication is as an adjunctive therapy to maintain abstinence in alcohol‑dependent patients who have already stopped drinking, usually combined with counselling or psychosocial support.

• Proper candidate profile:
  • Confirmed alcohol dependence.
  • Already abstinent or recently detoxified.
  • Motivated for relapse prevention and able to attend follow‑up.

Off‑label uses have been explored in subgroups or for protracted withdrawal symptoms, but evidence is limited; document the rationale clearly and discuss risks and benefits with the patient.

Use shared decision making and align treatment with local Australian guidelines and addiction services for final authority.

Key Clinical Findings & Evidence

Clinicians commonly ask how effective Campral is compared with placebo or other treatments.

Systematic reviews and meta‑analyses indicate acamprosate provides a modest benefit in maintaining abstinence versus placebo, especially when combined with psychosocial support.

Effects on reducing heavy drinking days are smaller than effects on sustained abstinence.

• Key counselling points:
  • The benefit is usually modest and accumulates over weeks.
  • Best results are seen when the patient is already abstinent before initiation.
  • Good adherence and psychosocial support improve outcomes.

Clinicians should consult the latest Cochrane reviews and national guidelines for exact effect sizes and implementation details in the Australian setting.

Alternatives Matrix

Patients often wonder whether Campral is the only option for relapse prevention.

Principal pharmacological alternatives include naltrexone (oral or depot) and disulfiram, while psychosocial interventions remain core treatment components.

• Pros/cons checklist: consider hepatic vs renal function, whether blocking reward is desired, adherence feasibility, and safety in overdose.

Refer to an addiction specialist when first‑line options fail or comorbidity complicates treatment choice.

Common Pharmacy & Patient Questions (FAQs From Australian Consultations)

Here are short, practical answers to questions heard most often in the pharmacy.

How long before it works?

Benefit is gradual and typically appears over several weeks when combined with counselling.

What are the common side effects?

Gastrointestinal upset, diarrhoea and headache are among the most reported adverse effects.

Can I drink while taking it?

No; Campral is intended for patients who are already abstinent and continued drinking reduces efficacy.

Is Campral addictive?

No; acamprosate is not considered addictive.

Can I take it with other medicines?

Pharmacokinetic interactions are few, but check renal function and review CNS depressants and nephrotoxic drugs.

Pregnancy and breastfeeding?

Data are limited; seek specialist advice.

• Follow‑up checklist: review adherence at 2–4 weeks, monitor renal function at baseline and periodically, assess mood and suicidal ideation.

Provide written leaflets and referral contacts such as local alcohol services and Lifeline for crisis support.

Price & Access Comparison

Costs and subsidy status change — always verify current listings.

• Checklist for cost‑sensitive patients: check PBS eligibility and concession card status, compare suppliers, consider PBS‑covered alternatives, and discuss adherence supports such as dose administration aids.

For rural or remote patients coordinate supply with community health services to maintain continuity of therapy.

Registration & Regulation (TGA, PBS Guidance)

Clinicians and pharmacists should verify registration and subsidy details before prescribing or dispensing.

• Regulatory checks to perform:
  • Confirm ARTG entry for the product.
  • Check current PBS listing and any authority codes.
  • Verify approved indications in the Australian product information.

Ensure the supplied product matches the prescription and any PBS authority requirements at the time of supply.

ARTG

The Australian Register of Therapeutic Goods entry for marketed medicines; check before advising on availability.

PBS

Pharmaceutical Benefits Scheme listing determines subsidy and authority rules; verify current status.

Keep a copy of the current Australian product information on file and subscribe to TGA and PBS updates for safety notices and listing changes.

Storage & Handling (Household And Pharmacy In Australian Climate)

Patients frequently ask how to store Campral in hot or humid weather.

Store at ambient room temperature and protect from moisture and heat; avoid storing in bathrooms.

In hot or humid Australian climates advise keeping the medicine below 25–30°C and out of direct sunlight.

Keep tablets in the original blister pack until use and return any discoloured or damaged tablets to the pharmacy.

Pharmacy handling does not require cold chain; standard ambient storage with humidity control in the dispensary is appropriate.

Use first‑expiring, first‑out (FEFO) procedures and track batch numbers and expiry dates.

• Patient counselling checklist: where to keep medicine, what to do if a dose is vomited (do not repeat dose; take next scheduled dose), and how to transport medication when travelling (carry a copy of the prescription).

Guidelines For Proper Use & Pharmacist Counselling Style

Patients benefit from a structured, empathetic counselling approach.

Follow this counselling framework: confirm abstinence and readiness, explain purpose and expected timeline, review dosing schedule and missed dose instructions, screen and refer for psychosocial support, and arrange follow‑up and monitoring.

• Use this pharmacy consultation checklist:
  • Confirm last drink and current abstinence.
  • Review renal function results and baseline tests.
  • Discuss side effects and when to seek urgent care.
  • Provide written plan with helplines and local services.

Use culturally safe, non‑judgemental language and involve family or support persons only with the patient’s consent.

Offer adherence supports such as dose administration aids or blister packing and liaise with the prescriber if adherence issues arise.

Delivery Across Australia